SCHEMBL27201546

SCHEMBL27201546

CN(C)CCCNC(=O)c1csc(Br)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.57
KDM4E B2RXH2 5/20 0.51
HPGD P15428 4/20 0.51
ALDH1A1 P00352 4/20 0.51
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 2/20 0.46
MAPT P10636 1/20 0.46
AGTR1 P30556 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TSHR P16473 1/20 0.46
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12124376 0.84 USP2 (0.58) USP2KDM4EHPGDALDH1A1NPC1
SCHEMBL25233005 0.82 HPGD (0.46) USP2KDM4EHPGDALDH1A1NPC1
SCHEMBL7217724 0.77 L3MBTL1 (0.48) USP2HPGDALDH1A1NPC1RAB9A
SCHEMBL10020214 0.76 HPGD (0.79) KDM4EHPGDALDH1A1NPC1RAB9A
SCHEMBL12124238 0.75 USP2 (0.69) USP2KDM4EHPGDALDH1A1NPC1
SCHEMBL31245842 0.74 HPGD (0.57) KDM4EHPGDALDH1A1NPC1RAB9A
SCHEMBL24849909 0.74 HPGD (0.57) KDM4EHPGDALDH1A1NPC1RAB9A
SCHEMBL26469193 0.74 GAA (0.56) USP2KDM4EHPGDALDH1A1NPC1
SCHEMBL7886628 0.73 HPGD (0.57) KDM4EHPGDALDH1A1NPC1RAB9A
SCHEMBL29545594 0.73 HPGD (0.56) USP2KDM4EHPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP USP2 93/4885KDM4E 1293/4885HPGD 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.